This study looks at how well and safely galcanezumab, a medicine, works for children and teens aged 6-17 who have episodic migraines. A migraine is a type of headache that can make you feel sick and sensitive to light. The study has two parts: the main study and a study addendum.

The main study lasts 3 months where participants either get galcanezumab or a placebo (a fake treatment) without knowing which one, followed by 9 months where everyone gets galcanezumab. The study addendum involves a one-time shot of galcanezumab and then checks how it works in the body over 5 months, followed by a 9-month extension where everyone receives the medicine.

• The study is open to those with a migraine history of at least 6 months.
• Participants cannot join if using certain other medicines or have specific health conditions.
• Joining this study may involve visits and receiving injections.

Participation is voluntary, and parents should consider the time commitment and any potential risks or benefits.